Blenrep Belantamab Mafodotin Application Scope

Indicated for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received prior therapies including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression.

Belantamab Mafodotin Characteristics

Ingredients: Belantamab mafodotin-blmf
Properties: Belantamab mafodotin is a white to off-white lyophilized powder that forms a clear to slightly opalescent solution for intravenous infusion after reconstitution.
Packaging Specification: Typically supplied as 100 mg per single-dose vial
Storage: Store Belantamab mafodotin at 2°C–8°C under refrigeration, protect from light, do not freeze, and use the reconstituted solution within the recommended time period.
Expiry Date: Generally 24 months (subject to batch-specific labeling)
Executive Standard: Complies with ICH guidelines and regulatory standards (e.g., FDA BLA, EMA EPAR, NMPA)
Approval Number: Approval status varies; may be accessible under special programs
Date of Revision: Based on latest prescribing information updates (post-2022 revisions)
Manufacturer: GlaxoSmithKline (GSK)

Guidelines for the Use of Blenrep

Dosage and Administration:
- Recommended Dose: Blenrep is administered at a recommended dose of 2.5 mg/kg intravenously once every 3 weeks (Q3W).
- Administration: Administer as an intravenous infusion over approximately 30 minutes, with an ophthalmic examination required prior to each dose; premedication is not routinely necessary unless clinically indicated.
- Missed Dose: If a dose is missed, administer as soon as possible, adjust the dosing schedule accordingly, and avoid dose doubling.
Adverse Reactions:
- Common Adverse Reactions: Common adverse reactions of Blenrep include keratopathy (corneal epithelium changes), blurred vision, thrombocytopenia, anemia, nausea, and fatigue.
- Serious Adverse Reactions: Serious adverse reactions include severe ocular toxicity (which may lead to vision loss), severe thrombocytopenia with bleeding risk, and infusion-related reactions.
Contraindications: Hypersensitivity to belantamab mafodotin or any excipients
Precautions:
- mandatory regular eye examinations
- Use preservative-free artificial tears during treatment
- Dose modification or interruption may be required based on ocular findings
- Embryo-fetal toxicity: avoid use during pregnancy
- Discontinue breastfeeding during treatment

Belantamab Mafodotin Interactions

No formal clinical drug–drug interaction studies have been conducted for Belantamab mafodotin
Not significantly metabolized by cytochrome P450 (CYP) enzymes
Clinically relevant pharmacokinetic interactions are unlikely
Use caution with concomitant drugs that may increase ocular toxicity
Use caution with agents that may increase the risk of thrombocytopenia

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.